Stay updated on Low Dose Sulindac & Eflornithine for FAP Clinical Trial
Sign up to get notified when there's something new on the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page.

Latest updates to the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe record now presents details of the withdrawn phase III FAP study, including its eligibility criteria, treatment arms, and outcome measures, instead of an error page.SummaryDifference47%

- Check20 days agoChange DetectedThe footer revision identifier was updated from v3.7.2 to v3.8.0. The study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide notice announces an NIH website transition and says federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) during the transition.SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, presenting a generic error screen and site footer.SummaryDifference18%

Stay in the know with updates to Low Dose Sulindac & Eflornithine for FAP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page.